Please login to the form below

Not currently logged in
Email:
Password:

Merck and Co

This page shows the latest Merck and Co news and features for those working in and with pharma, biotech and healthcare.

AZ swells immuno-oncology pipeline with Innate deal

AZ swells immuno-oncology pipeline with Innate deal

Moreover, with AZ still playing catch-up in the immuno-oncology category with the likes of Merck &Co/MSD and Bristol-Myers Squibb, the company has also agreed to pay $50m ... There’s also some money flowing in the other direction, as Innate is

Latest news

  • Merck’s Bavencio joins first-line kidney cancer face-off Merck’s Bavencio joins first-line kidney cancer face-off

    Merck’ s Bavencio joins first-line kidney cancer face-off. PD-L1 and TKI combination could challenge standard of care. ... Combine that with the positive data reported last week with the combination of Merck &Co/MSD’s Keytruda (pembrolizumab) and

  • AZ and Clovis PARP inhibitors show their mettle at ESMO AZ and Clovis PARP inhibitors show their mettle at ESMO

    over 50% of women on the olaparib arm were still progression free at four years as compared to only 11% for placebo speaks to this hope, ”said SOLO-1 co-principal ... AZ and its Lynparza marketing partner Merck &Co/MSD, say they are now “working with

  • Merck & Co picks Nike exec to be digital transformation leader Merck & Co picks Nike exec to be digital transformation leader

    Merck &Co picks Nike exec to be digital transformation leader. Cyber-security and customer focus will be key issues. ... Merck &Co has appointed Nike’s Jim Scholefield to be its new chief information and digital officer, continuing a trend in pharma to

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    In immuno-oncology, this year’s offering includes a first showing for data in first-line advanced renal cell carcinoma for Merck KGaA/Pfizer’s Bavencio (avelumab) in the JAVELIN Renal ... Merck &Co/MSD – already dominating non-small cell lung

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    Bristol-Myers Squibb’s Opdivo and Merck &Co/MSD’s Keytruda. ... Meanwhile, Merck filed an application for Keytruda in the US in June as an adjuvant therapy based on the KEYNOTE-054 trial.

More from news
Approximately 46 fully matching, plus 453 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Checkpoint inhibitors – old and new. The first wave of checkpoint inhibitors targeting PD-(L) 1 and CTLA-4, from Bristol-Myers Squibb, Merck &Co, Roche, AstraZeneca and Merck KGaA/Pfizer, have ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor

  • Advancing women in healthcare Advancing women in healthcare

    Taking on the mantle of HBA’s Woman of the Year 2018 is Julie Gerberding, Merck &Co’s chief patient officer, and head of global public policy and population health. ... She joined Merck &Co in 2009 and sees her role in promoting vaccines and

  • The good, the bad and the ugly The good, the bad and the ugly

    Beyond Pfizer, the biggest positive movers in the top 20 include Shire, Bayer and Merck &Co. ... 2020.”. Central Nervous System. 2017 was a quiet year in CNS. The most prominent growing companies were Merck &Co (49.8%), Takeda (39.1%) and Sumitomo

  • Deal Watch - May 2017 Deal Watch - May 2017

    More recent data reported in FiercePharma (1. st. May) shows Amgen has cash overseas of $34bn, Gilead $27bn and Merck &Co $22bn. ... It has signed deals with 10 companies in the last two years including Novartis, Genentech, Sanofi, Merck &Co and Lilly.

  • Deal Watch September 2016 Deal Watch September 2016

    Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... 600. Verily / Sanofi. JV. Co-investment to form Onduo combining Sanofi's diabetes expertise with Verily

More from intelligence
Approximately 0 fully matching, plus 36 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Hansa Medical poaches Vifor Pharma’ s CEO. Søren Tulstrup becomes the Swedish biopharma’s CEO and president. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in several senior commercial roles within Merck &Co

  • Astellas promotes Anthony Fiordaliso to VP, Americas finance Astellas promotes Anthony Fiordaliso to VP, Americas finance

    He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president

  • Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

    Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel. They will join the board of directors. ... Verwiel has also served at Merck &Co, where he was vice president and was general manager at Merck Sharpe Dohme’s operations in the

More from appointments
Approximately 4 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics